Barchart Research What to Expect from ATAI Earnings ATAI Generated May 12, 2026 Current Price $4.15 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 7.37% AtaiBeckley's Phase Three Initiation...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements...
Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by...
From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.
Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.
2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.
Wall Street still sees triple-digit upside in this high-risk biotech bet.
– Co-Founder Maximilian Martin Appointed CEO –
As policy meets potential in North Carolina, Atai Life Sciences could be a solid portfolio addition now.